Prayagraj: Associate professor in department of cardiology, MLN Medical College, Dr Abhishek Sachdeva, delivered a lecture on ‘Introducing Yurpeak (Tirzepatide) for Weight Management: Novel GIP & GLP-1 Receptor Agonist’ at AMA auditorium, on Sunday.He said, “Tirzepatide is a weekly injection that helps manage weight by reducing appetite and increasing feeling of fullness. It is effective in adults with obesity or weight-related health problems (such as diabetes), along with a reduced-calorie diet and exercise.”He added that it was a GIP (gastric inhibitory peptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, which signals brain to reduce appetite and slow down digestion.
This is primarily for people who have BMI of 30 or higher, or a BMI of 27 or higher and also have a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.Meanwhile, senior endocrinologist and assistant professor, department of endocrinology, MLN Medical College, Dr Vibhu Ranjan Khare, delivered his lecture on ‘Redefine the Peak: Setting New Expectations for Type 2 Diabetes Management with Tirzepatide”. He spoke about compounded Tirzepatide to treat diabetes.According to him, Tirzepatide was a powerful, once-a-week injectable medication for type 2 diabetes acts as a dual agonist for both GIP and GLP-1 receptors, significantly improving blood sugar control (lowering HbA1c) and promoting substantial weight loss, often more effectively than GLP-1 agonists alone. It works by boosting glucose-dependent insulin release, slowing stomach emptying, and increasing satiety, helping to manage hyperglycaemia and insulin resistance.
It is used alongside diet and exercise and is also approved for weight management in obesity. tnn
